A 2009 federal sting showed clinical-trial ethics boards could be manipulated. A new nonprofit says the fix is who pays them.

Before any clinical trial in the United States can enroll a patient, an independent ethics board is supposed to sign off that the study treats its participants safely and honestly. In 2009, federal investigators tested whether that gatekeeper actually worked, and found a hole that two veteran research ethicists say has never been properly closed.

The investigators, working for the U.S. Government Accountability Office, submitted a fictitious clinical-trial protocol to three for-profit institutional review boards, or IRBs. The protocol described a fake medical device that met several of the Food and Drug Administration's criteria for "significant risk." One of the boards, Coast IRB, approved it. The GAO's subsequent testimony described the oversight system as vulnerable to "unethical manipulation," a finding ethicists say describes a structural flaw, not a personnel problem.

The flaw, Rosenfeld and Seymour argue, is financial. The boards that review U.S. clinical research are paid by the very institutions whose research they are supposed to police. Most of the time the arrangement works. But when the money flows from the institution to the reviewer, the system creates a built-in pressure to keep trials moving, even ones whose scientific or ethical merit is shaky. As Rosenfeld told STAT: "It's very hard to figure out how to do this review, pay for it, and avoid structural conflicts of interest."

That is the argument behind the nonprofit the two are launching this month, the North Star Review Board, a 501(c)(3) registered with the IRS under EIN 85-1988657. North Star operates as a "Research Ethics Review Board," or RERB, its term for an IRB outside the academic medical-center system, and is built to take investor-return pressure out of the review function. The founders describe the model as architectural: remove the financial relationship that creates the conflict, rather than police individual cases after the fact.

The two have spent decades in this corner of research ethics. Rosenfeld is a long-time consultant on clinical-trial design and previously ran the research ethics program at a large academic medical center. Seymour has advised on trial design and IRB reform. Both describe the venture as an attempt to redesign the gatekeeping relationship rather than add another layer of case-by-case policing.

The reform lands in a system that is showing strain. Academic medical centers, which operate the largest IRBs in the country, are facing historic financial pressure, and trust between research institutions and the federal government is fractured in ways not seen in a generation. Independent, for-profit IRBs have proliferated to handle the volume of industry-sponsored research, and ethicists interviewed by STAT say the work of review has drifted toward facilitating speed and legal compliance rather than protecting participants, a criticism STAT documented in a 2024 investigation of IRBs failing to assess the scientific merit of the trials they approved.

Whether a small nonprofit can shift that balance is an open question. The 2009 sting targeted three for-profit boards; seventeen years later, the same financial arrangement remains the norm for most industry-sponsored research. Coast IRB became a case study in what the GAO warning described, and the structural critique applies to the model, not just one operator. North Star has signaled an unusual level of operational transparency for the field, publishing its review criteria, decision timelines, and conflict-of-interest policies, and plans to start with a small caseload.

A first review under the new model is expected later this year. The 2009 GAO finding, that the U.S. system for protecting research participants is structurally vulnerable, is still on the public record. North Star's bet is that the fix is a board paid in a way that does not depend on the verdict it delivers. The next several months will tell the field whether the rest of clinical research is willing to fund the answer.